Show Notes
Help Shape What’s Next on Retina Synthesis Tell us what you enjoy and what you’d like to hear more of. Our listener survey is anonymous and takes under 3 minutes. Your feedback will help guide future episodes. Take the survey: https://docs.google.com/forms/d/e/1FAIpQLSfPvwGmK_zEzF7x5f7bBM78nCsYLyS6Ga3jrJMAHg2FmvtLng/viewform Thank you for being part of the Retina Synthesis community! Dr. Raj Maturi of Midwest Eye Institute and Indiana University School of Medicine discusses the 12-month Phase...
More from Retina Synthesis
Dr. Ashkan Abbey, Director of Clinical Research at Texas Retina Associates, returns to discuss vonaprument (ANX007), a C1q inhibitor that blocks complement upstream of C3 and C5. In Phase 2 ARCHER, monthly treatment cut the risk of ≥15-letter vision loss by about 73% and preserved photoreceptors on OCT, while lesion growth on autofluorescence did not change. He explains the Phase 3 ARCHER II design — 659 patients, dual primary endpoints at months 15 and 24 — the low-luminance phenotype that r...
Can a drop replace the needle in diabetic macular edema? Dr. Veeral Sheth returns to Retina Synthesis to walk through DIAMOND-1 and DIAMOND-2, Oculis's twin Phase 3 trials of OCS-01, a high-concentration (15 mg/mL) topical dexamethasone formulated to reach the posterior segment. Across 800+ patients with mild-to-moderate DME, the drop did what it was supposed to do anatomically — central thickness fell quickly and stayed down for 52 weeks — yet both trials missed the week-52 visual acuity end...
We welcome back Dr. Roger Goldberg from Bay Area Retina Associates, in our latest episode to discuss the BARDENAS trial (NCT05151744) a global Phase 2 clinical study evaluating the efficacy and safety of vamikibart (RO7200220), an IL-6 inhibitor, combined with ranibizumab for treating diabetic macular edema (DME).
In this episode, we discuss the surgical technique and complications associated with implantation of an encapsulated cell therapy for MacTel 2 with Dr. Lloyd Clark from North Carolina Retina Association.
In this episode, we discuss the results of the Phase 3 Lugano Trial from Eyepoint Pharmaceuticals with Dr. Carl Regillo of Wills Eye Hospital.